The long noncoding RNA MSNP1AS (moesin pseudogene 1, antisense) is a functional element that was previously associated with autism spectrum disorder (ASD) with genome-wide significance. Expression of MSNP1AS was increased 12-fold in the cerebral cortex of individuals with ASD and 22-fold in individuals with a genome-wide significantly associated ASD genetic marker on chromosome 5p14.1. Overexpression of MSNP1AS in human neuronal cells caused decreased expression of moesin protein, which is involved in neuronal process stability. In this study, we hypothesize that MSNP1AS knockdown impacts global transcriptome levels. We transfected the human neural progenitor cell line SK- N-SH with constructs that caused a 50% suppression of MSNP1AS expression. After 24 h, cells were harvested for total RNA isolation. Strand-specific RNA sequencing analysis indicated altered expression of 1,352 genes, including altered expression of 318 genes following correction for multiple comparisons. Expression of the OAS2 gene was increased >150-fold, a result that was validated by quantitative PCR. Gene ontology analysis of the 318 genes with altered expression following correction for multiple comparisons indicated that upregulated genes were significantly enriched for genes involved in immune response, and downregulated genes were significantly enriched for genes involved in chromatin remodeling. These data indicate multiple transcriptional and translational functions of MSNP1AS that impact ASD-relevant biological processes. Chromatin remodeling and immune response are biological processes implicated by genes with rare mutations associated with ASD. Our data suggest that the functional elements implicated by association of common genetic variants impact the same biological processes, suggesting a possible shared common molecular pathway of ASD.

1.
Levitt P, Campbell DB: The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. J Clin Invest 2009;119:747-754.
2.
Wilkinson B, Campbell DB: Contribution of long noncoding RNAs to autism spectrum disorder risk. Int Rev Neurobiol 2013;113:35-59.
3.
Wang K, Zhang H, Ma D, Bucan M, Glessner JT, Abrahams BS, Salyakina D, Imielinski M, Bradfield JP, Sleiman PM, Kim CE, Hou C, Frackelton E, Chiavacci R, Takahashi N, Sakurai T, Rappaport E, Lajonchere CM, Munson J, Estes A, Korvatska O, Piven J, Sonnenblick LI, Alvarez Retuerto AI, Herman EI, et al: Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature 2009;459:528-533.
4.
Barnard RA, Pomaville MB, O'Roak BJ: Mutations and modeling of the chromatin remodeler CHD8 define an emerging autism etiology. Front Neurosci 2015;9:477.
5.
Wilkinson B, Grepo N, Thompson BL, Kim J, Wang K, Evgrafov OV, Lu W, Knowles JA, Campbell DB: The autism-associated gene chromodomain helicase DNA-binding protein 8 (CHD8) regulates noncoding RNAs and autism-related genes. Transl Psychiatry 2015;5:e568.
6.
DeWitt J, Campbell DB: Targeting noncoding RNA for treatment of autism spectrum disorders; in Hu V (ed): Frontiers in Autism Research, Diagnosis, and Treatment. Singapore, World Scientific Publishing, 2014, pp 203-228.
7.
Kerin T, Ramanathan A, Rivas K, Grepo N, Coetzee GA, Campbell DB: A noncoding RNA antisense to moesin at 5p14.1 in autism. Sci Transl Med 2012;4:128ra140.
8.
St Pourcain B, Wang K, Glessner JT, Golding J, Steer C, Ring SM, Skuse DH, Grant SF, Hakonarson H, Davey Smith G: Association between a high-risk autism locus on 5p14 and social communication spectrum phenotypes in the general population. Am J Psychiatry 2010;167:1364-1372.
9.
Jiang J, Jing Y, Cost GJ, Chiang JC, Kolpa HJ, Cotton AM, Carone DM, Carone BR, Shivak DA, Guschin DY, Pearl JR, Rebar EJ, Byron M, Gregory PD, Brown CJ, Urnov FD, Hall LL, Lawrence JB: Translating dosage compensation to trisomy 21. Nature 2013;500:296-300.
10.
Turner AM, Ackley AM, Matrone MA, Morris KV: Characterization of an HIV-targeted transcriptional gene-silencing RNA in primary cells. Hum Gene Ther 2012;23:473-483.
11.
Hawkins PG, Morris KV: Transcriptional regulation of OCT4 by a long non-coding RNA antisense to OCT4-pseudogene 5. Transcription 2010;1:165-175.
12.
Hawkins PG, Santoso S, Adams C, Anest V, Morris KV: Promoter targeted small RNAs induce long-term transcriptional gene silencing in human cells. Nucleic Acids Res 2009;37:2984-2995.
13.
Knowling S, Morris KV: Non-coding RNA and antisense RNA. Nature's trash or treasure? Biochimie 2011;93:1922-1927.
14.
Trapnell C, Pachter L, Salzberg SL: Tophat: discovering splice junctions with RNA-seq. Bioinformatics 2009;25:1105-1111.
15.
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R: Genome Project Data Processing S: the sequence alignment/map format and samtools. Bioinformatics 2009;25:2078-2079.
16.
Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L: Transcript assembly and quantification by RNA-seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010;28:511-515.
17.
Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
18.
Huang da W, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37:1-13.
19.
Abrahams BS, Arking DE, Campbell DB, Mefford HC, Morrow EM, Weiss LA, Menashe I, Wadkins T, Banerjee-Basu S, Packer A: SFARI gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs). Mol Autism 2013;4:36.
20.
Lee H, Lin MC, Kornblum HI, Papazian DM, Nelson SF: Exome sequencing identifies de novo gain of function missense mutation in KCND2 in identical twins with autism and seizures that slows potassium channel inactivation. Hum Mol Genet 2014;23:3481-3489.
21.
De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, Kou Y, Liu L, Fromer M, Walker S, Singh T, Klei L, Kosmicki J, Shih-Chen F, Aleksic B, Biscaldi M, Bolton PF, Brownfeld JM, Cai J, Campbell NG, Carracedo A, Chahrour MH, Chiocchetti AG, Coon H, Crawford EL, Curran SR, Dawson G, et al: Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014;515:209-215.
22.
Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL: Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 2011;25:1915-1927.
23.
Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P, Brown JB, Lipovich L, Gonzalez JM, Thomas M, Davis CA, Shiekhattar R, Gingeras TR, Hubbard TJ, Notredame C, Harrow J, Guigo R: The Gencode v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012;22:1775-1789.
24.
Guttman M, Rinn JL: Modular regulatory principles of large non-coding RNAs. Nature 2012;482:339-346.
25.
Ravasi T, Suzuki H, Pang KC, Katayama S, Furuno M, Okunishi R, Fukuda S, Ru K, Frith MC, Gongora MM, Grimmond SM, Hume DA, Hayashizaki Y, Mattick JS: Experimental validation of the regulated expression of large numbers of non-coding RNAs from the mouse genome. Genome Res 2006;16:11-19.
26.
Mercer TR, Dinger ME, Sunkin SM, Mehler MF, Mattick JS: Specific expression of long noncoding RNAs in the mouse brain. Proc Natl Acad Sci USA 2008;105:716-721.
27.
Batista PJ, Chang HY: Long noncoding RNAs: cellular address codes in development and disease. Cell 2013;152:1298-1307.
28.
Karreth FA, Pandolfi PP: ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov 2013;3:1113-1121.
29.
Lee JT: Epigenetic regulation by long noncoding RNAs. Science 2012;338:1435-1439.
30.
Mattick JS, Rinn JL: Discovery and annotation of long noncoding RNAs. Nat Struct Mol Biol 2015;22:5-7.
31.
Mercer TR, Dinger ME, Mattick JS: Long non-coding RNAs: insights into functions. Nat Rev Genet 2009;10:155-159.
32.
Morris KV, Mattick JS: The rise of regulatory RNA. Nat Rev Genet 2014;15:423-437.
33.
Orom UA, Shiekhattar R: Long noncoding RNAs usher in a new era in the biology of enhancers. Cell 2013;154:1190-1193.
34.
Prensner JR, Chinnaiyan AM: The emergence of lncRNAs in cancer biology. Cancer Discov 2011;1:391-407.
35.
Ulitsky I, Bartel DP: lincRNAs: genomics, evolution, and mechanisms. Cell 2013;154:26-46.
36.
Akbarian S, Liu C, Knowles JA, Vaccarino FM, Farnham PJ, Crawford GE, Jaffe AE, Pinto D, Dracheva S, Geschwind DH, Mill J, Nairn AC, Abyzov A, Pochareddy S, Prabhakar S, Weissman S, Sullivan PF, State MW, Weng Z, Peters MA, White KP, Gerstein MB, Amiri A, Armoskus C, Ashley-Koch AE, Bae T, et al: The PsychENCODE project. Nat Neurosci 2015;18:1707-1712.
37.
Bourgeron T: From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nat Rev Neurosci 2015;16:551-563.
38.
Ashwood P, Wills S, Van de Water J: The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006;80:1-15.
39.
De Jong S, Newhouse SJ, Patel H, Lee S, Dempster D, Curtis C, Paya-Cano J, Murphy D, Wilson CE, Horder J, Mendez MA, Asherson P, Rivera M, Costello H, Maltezos S, Whitwell S, Pitts M, Tye C, Ashwood KL, Bolton P, Curran S, McGuffin P, Dobson R, Breen G: Immune signatures and disorder-specific patterns in a cross-disorder gene expression analysis. Br J Psychiatry 2016;209:202-208.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.